Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Foeniculum vulgare seed, commonly known as fennel seed, is a botanical substance derived from the *Foeniculum vulgare* plant, widely recognized for its culinary and medicinal applications. It contains a complex mixture of bioactive compounds, including trans-anethole, fenchone, estragole, and various flavonoids and phenolic acids. Research indicates that fennel seed extracts exhibit significant pharmacological activities, including anti-inflammatory, antioxidant, and estrogenic effects. In preclinical oncology studies, extracts have demonstrated the ability to inhibit the growth of hepatocellular carcinoma and lung cancer cells by downregulating anti-apoptotic proteins such as Bcl-2 and survivin, thereby triggering mitochondrial-mediated apoptosis. Additionally, the seed extract has shown potential in managing polycystic ovary syndrome (PCOS) and providing neuroprotection against lead-induced toxicity. It is also known to interact with drug-metabolizing enzymes, specifically acting as a mechanism-based inhibitor of CYP3A4 and CYP2D6.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on foeniculum vulgare seed.